This Perspective calls for inclusion of patients with MASLD and measurement of liver outcomes in cardio–kidney–metabolic trials, when data suggest mechanistically plausible benefits and clinical safety—and outlines considerations for trial design and regulatory approval.
- Faiez Zannad
- Arun J. Sanyal
- Stephen A. Harrison
